Why is it concerning? Three main reasons:
1. The place: P.1 is spreading in Manaus, which is experiencing a devastating surge after already experiencing a terrible wave of infections in March/April. @DrMikeRyan described the dire situation yesterday: https://twitter.com/kakape/status/1350145043340931081
2. The mutations: P.1 carries several mutations in the spike protein like E484K, K417T, and N501Y, that have been linked in the lab to escape from antibodies or better binding to cells. Remember though that we know little about how these mutations alone impact virus in real life.
We know even less about what they mean together. As @K_G_Andersen told me about N501Y (Nelly): “Nelly might be innocent, except maybe when she’s hanging with her bad friends”. This is why the urgent task is to understand constellations of mutations not just individual mutations.
3. The similarity: The pattern of mutations of P.1 is similar to that found in another varian of concern: N501Y.V2, the variant first identified in South Africa. Both have N501Y and E484K and both have a mutation at position 417 (though a different one).
And as @jessebloom told me: “Anytime you see the same mutations arising and starting to spread multiple times, in different viral strains across the world, that’s really strong evidence that there’s some evolutionary advantage to those mutations.”
IF 75% were already infected in Manaus, then 3 ways to explain surge, @EvolveDotZoo told me:
1. P.1 doesn’t matter. Immunity is waning and people are getting infected again.
2. P.1 is better at reinfecting people.
3. P.1 is more transmissible (threshold for herd immunity higher)
It could, of course, also be a combination of these three factors. But it should be clear from this why the situation around P.1 is concerning and why figuring out what is going on in Manaus is one of the urgent puzzles of this pandemic.
Even if P.1 and/or 501Y.V2 turn out to be better at reinfecting people that would likely be a gradual effect. It also doesn’t mean they are resistant to the vaccines. But that we are even talking about it is a warning sign. We need to adjust expectations and we need to prepare.
As @BillHanage told me: "We spent months talking about how slow the mutation rate is. I think it is smart to get ready to make different vaccines, and smooth regulatory pathways, so that we can plug-and-play. Because this is going to keep happening.”
Make no mistake: Most researchers I talk to agree on this. And it marks a shift. This shift is not simply due to mutations accruing which was to be expected. It’s because we are seeing the virus essentially make evolutionary “leaps” to certain combinations of worrying mutations.
So what is needed? Basically what @WHO’s emergency committee called for:
More genomic surveillance and sharing of the data.
More research into what these variants really mean. (UK’s new consortium G2P-UK seems like a good start, but more needed.)
Finally, a word about B.1.1.7, the variant first identified in England. The evidence has become stronger and stronger over time that this is more transmissible (but it likely has litte effect on immunity).
You can follow @kakape.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.